World Rare Disease Day: GEXVal Presents Posters at 5th Tsukuba Co-creation Conference  

2026/3/3 Last updated : 2026/7/22 wpmaster

GEXVal Inc.
March 3, 2026

World Rare Disease Day: GEXVal Presents Two Posters at 5th Tsukuba Co-creation Conference

 

GEXVal Inc. (President & CEO: Juran Kato, PhD; Fujisawa, Kanagawa, Japan; hereinafter “GEXVal”) is pleased to announce that that, in observance of World Rare Disease Day, it participated in the 5th Tsukuba Co-creation Conference, held at the Astellas Pharma Tsukuba Research Center (Tsukuba, Ibaraki, Japan), and presented two posters at the poster session.

[Event Overview]
The Tsukuba Co-creation Conference is a collaborative forum jointly hosted by five pharmaceutical companies with research facilities in Tsukuba (Astellas Pharma, Eisai, Ono Pharmaceutical, Taiho Pharmaceutical, and Nippon Shinyaku) and the University of Tsukuba Co-creation Place. The 5th Conference was held under the theme "Rare Disease Conditions — Creating a Future Where No One Is Left Behind," bringing together patient advocates, clinical researchers, basic scientists, and pharmaceutical industry professionals to share perspectives on the challenges and unmet needs in rare condition diagnosis and treatment.

**Presentation Details**

Conference

The 5th Tsukuba Co-Creation Conference
Rare Diseases: Building a Future Where No One Is Left Behind

Date

March 3, 2026

Venue

Astellas Pharma Inc., Tsukuba Research Center

Poster Presentation
  • Data-Driven Indication Discovery for Rare Diseases Using AI Agent Technology
    • Yusuke Nakayama1, Shingo Tsuji2, Koji Yamamoto3, Juran Kato1, and Kouichi Hosomi4
    • 1GEXVal Inc.; 2RCAST, The University of Tokyo; 3Independent Researcher; 4Faculty of Pharmacy, Kindai University
  • Preclinical and Clinical Evaluation of a Novel GPCR Modulator in Fragile X Syndrome
    • Takako Naito1, Yusuke Nakayama1, Takashi Arima1, Guido Hanauer1, Ajay Duggal1, 2, Kim Prescott1, 2, Mike Tranfaglia3, 4, Patricia Cogram4, and Juran Kato-Suzuki1, 5
    • 1GEXVal Inc.; 2Adnovate Clinical; 3FRAXA Research Foundation; 4FRAXA Drug Validation Initiative and Institute of Ecology and Biodiversity, University of Santiago, Chile; 5GEXVal AU Pty Ltd

 

[About GEXVal]
GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology, we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.

For further information:
Head of Corporate Office
Atsushi Sugizaki
info@gexval.com

Categories
Information
Previous article
Rare Disease Day Update: FRAXA Features GEXVal’s FRAXA-DVI Completion and FDA Orphan Drug Designation
2026/2/28
Next article
CTO Nakayama Contributes Invited Article to Experimental Medicine, Japan’s Leading Life Science Journal, on AI-Driven Drug Discovery
2026/3/12